Loading
Some tumours have broken the machinery that displays their identity to immune cells. Those patients cannot benefit from most immunotherapy and should be routed elsewhere.
Loss of HLA heterozygosity, B2M mutation, JAK1/2 loss and antigen presentation machinery defects are recurrent mechanisms of primary and acquired checkpoint resistance, and each is detectable from sequencing of tumour and germline. Routine reporting of an antigen presentation integrity score would identify patients who should be routed to HLA-independent therapies such as antibody-drug conjugates, natural killer cell engagers or CAR products.
Shares OncoKB, AACR Project GENIE, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy.
Shares Ton Schumacher, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised.
Shares Neoantigen, Drug resistance (primary and acquired), No one can predict who responds to immunotherapy, Acquired resistance to every therapy.
Shares Charles Swanton, Drug resistance (primary and acquired), Acquired resistance to every therapy, Whole-exome & whole-genome sequencing.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised, Immune checkpoint inhibitors.
Shares AACR Project GENIE, Charles Swanton, Whole-exome & whole-genome sequencing.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised, Immune checkpoint inhibitors.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Comprehensive genomic profiling.